Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I)

Serruys, 2009, A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods, Lancet, 373, 897, 10.1016/S0140-6736(09)60325-1 Serruys, 2010, Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes, Circulation, 122, 2301, 10.1161/CIRCULATIONAHA.110.970772 Tamai, 2000, Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans, Circulation, 102, 399, 10.1161/01.CIR.102.4.399 Strandberg, 2012, Late positive remodeling and late lumen gain contribute to vascular restoration by a non-drug eluting bioresorbable scaffold: a four-year intravascular ultrasound study in normal porcine coronary arteries, Circ Cardiovasc Interv, 5, 39, 10.1161/CIRCINTERVENTIONS.111.964270 Ormiston, 2008, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet, 37, 899, 10.1016/S0140-6736(08)60415-8 Serruys, 2011, Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes, J Am Coll Cardiol, 58, 1578, 10.1016/j.jacc.2011.05.050 Diletti, 2013, Heart, 99, 98, 10.1136/heartjnl-2012-302598 Verheye, 2014, A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results, J Am Coll Cardiol Intv, 7, 89, 10.1016/j.jcin.2013.07.007 Ormiston, 2013, J Am Coll Cardiol Intv, 6, 1026, 10.1016/j.jcin.2013.05.013 Erbel, 2007, Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial, Lancet, 369, 1869, 10.1016/S0140-6736(07)60853-8 Haude, 2013, Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial, Lancet, 381, 836, 10.1016/S0140-6736(12)61765-6 Onuma, 2013, Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial, J Am Coll Cardiol Intv, 6, 999, 10.1016/j.jcin.2013.05.017 Bosiers, 2009, AMS INSIGHT—absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis, Cardiovasc Intervent Radiol, 32, 424, 10.1007/s00270-008-9472-8 Werner, 2014, Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study, J Am Coll Cardiol Intv, 7, 305, 10.1016/j.jcin.2013.09.009 Norgren, 2007, Inter-society consensus for the management of peripheral arterial disease (TASC II), Eur J Vasc Endovasc Surg, 33, S1, 10.1016/j.ejvs.2006.09.024 Krankenberg, 2007, Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST), Circulation, 116, 285, 10.1161/CIRCULATIONAHA.107.689141 Laird, 2010, Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial, Circ Cardiovasc Interv, 3, 267, 10.1161/CIRCINTERVENTIONS.109.903468 Laird, 2012, Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial, J Endovasc Ther, 19, 1, 10.1583/11-3627.1 Dake, 2011, Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results, Circ Cardiovasc Interv, 4, 495, 10.1161/CIRCINTERVENTIONS.111.962324 Dake, 2013, Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies, J Am Coll Cardiol, 61, 2417, 10.1016/j.jacc.2013.03.034 Werk, 2008, Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial, Circulation, 118, 1358, 10.1161/CIRCULATIONAHA.107.735985 Tepe, 2008, Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg, N Engl J Med, 358, 689, 10.1056/NEJMoa0706356 Scheinert, 2014, The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty, J Am Coll Cardiol Intv, 7, 10, 10.1016/j.jcin.2013.05.022 Tepe, 2015, Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial, Circulation, 131, 495, 10.1161/CIRCULATIONAHA.114.011004 Rosenfield, 2015, Trial of a paclitaxel-coated balloon for femoropopliteal artery disease, N Engl J Med, 373, 145, 10.1056/NEJMoa1406235 Lammer, 2012, Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature, J Vasc Surg, 55, 400, 10.1016/j.jvs.2011.08.048 Lammer, 2011, First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease, J Vasc Surg, 54, 394, 10.1016/j.jvs.2011.01.047